Lorlatinib can cause non-cardiogenic pulmonary edema as a rare adverse effect, which may respond to diuretic therapy and dose reduction.
Answers are grounded in this paper and cite their sources.
Lorlatinib may cause noncardiogenic pulmonary edema; this case leaves open incidence and rechallenge safety.
A 71-year-old woman was diagnosed with anaplastic lymphoma kinase-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis. Three weeks after the first dose, the patient was hospitalized because of lorlatinib-induced noncardiogenic pulmonary edema. The patient's condition improved with diuretic therapy, and lorlatinib was rechallenged at a reduced dose. Follow-up computed tomography revealed a partial response. This is a rare case of non-cardiogenic pulmonary edema as an adverse effect of lorlatinib.
No takes yet. Share an insight, caveat, or question.
Matsuoka et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: